Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy

Breast Cancer Research and Treatment

Volumn 55, Issue 2, 1999, Pages 107-117

  Gibson, Laura F ^a,c   Fortney, James ^a   Magro, Gabrielle ^a   Ericson, Solveig G ^a,b   Lynch, Joseph P ^a,b   Landreth, Kennneth S ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Apoptosis; Bax; Bcl 2; Breast cancer; Chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE DERIVATIVE; ETOPOSIDE; HYDROPEROXIDE DERIVATIVE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE G2 PHASE; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; HUMAN; HUMAN CELL; METAPHASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL CYCLE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTROGENS; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0032812605     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006175811676     Document Type: Article

References (24)

1. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Harden EA, Hande KR, Herzig GP: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473-479, 1990
2. Herzig RH, Lynch J, Christiansen NP, Fay JW, Davis MP, Herzing GP: Dose-intensive chemotherapy with etoposide-cylophosphamide for advanced breast cancer. Semin Oncol 23: 28-32, 1996
3. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, and other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362, 1990
4. Yamada T, Chyma H: Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). Int J Radiat Biol 53: 64-78, 1988
5. Alan DJ: Radiation-induced apoptosis: Its role in a MADCAT (mitosis-apoptosis differentiation-calcium toxicity) scheme of cytotoxicity mechanisms. Int J Radiat Biol 62: 145-152, 1992
6. Wyllie AH, Kerr JK, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 68: 251-305, 1980
7. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1958.
8. Tsujimoto Y, Gorham J, Cossman J, Jaffe B, Croce CM: The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393, 1985
9. Simonian PL, Grillot DAM, Nunez G: Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 90: 1208-1216, 1997
10. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994
11. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542, 1994
12. Chen M, Quintans J, Fuks Z, Thompson C, Kufe DW, Weichselbaum RR: Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α, and ceramide. Cancer Research 55: 991-994, 1995
13. L. J Biol Chem 37: 22764-22772, 1996
14. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagner C, Kallinich B, Royer HD, Doerken B: Expression of the Bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854-859, 1995
15. Chouhei S, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, Tsujimoto H, Imanishi T, Ohgaki M, Ohyama T, Yamazaki J, Hagiwara A, Yamaguchi T, Sawai K, Takahashi T: Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 67: 101-105, 1996
16. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Geller A, Royer HD, Dorken B: Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 97: 2652-2659, 1996
17. Wagener C, Bargou RC, Daniel PT, Bommert K, Mapara MY, Royer HD, Dorken B: Induction of the death-promoting gene Bax-α sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67: 138-141, 1996
18. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2: 275-280, 1990
19. Patel R, Twigg J, Crossley I, Golsteyn R, Whitaker M: Calcium-induced chromatin condensation and cyclin phosphorylation during chromatin condensation cycles in ammonia-activated sea urchin eggs. J Cell Sci S12: 129-144, 1989
20. Haldar S, Jena N, Croce CM: Inactivation of bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995
21. L or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 67: 608-614, 1996
22. Fattman CL, An B, Sussman L, Dou QP: p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. Cancer Lett 130: 103-113, 1998
23. Davidson K, Petit T, Izbicka E, Koester S, Von Hoff DD: Mitoguazone induces apoptosis via a p53-independent mechanism. Anticancer Drugs 9: 635-40, 1998
24. Gibson LF, Fortney J, Piktel D, Landreth KS, Lynch JP: Disruption of bone marrow stromal cell function by etoposide. Biology of Blood and Marrow Transplantation 3: 122-132, 1997